Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Lille, France Clinical Trials

A listing of Lille, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (383) clinical trials

A Multi-center Open-label Extension Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622

This is an open-label extension study to Study 200622.In this study subjects from Study 200622 will be continued on 4-weekly dosing with open-label mepolizumab 300 milligram (mg) subcutaneously (SC) for an additional 20 Weeks after completing the 32 Week study assessments post-randomization, while they continue with their background HES therapy ...

Phase

0.0 miles

Learn More »

Study of BIIB092 in Participants With Progressive Supranuclear Palsy

This study, previously posted by Bristol-Myers Squibb, has transitioned to Biogen under a licensing agreement.

Phase

0.0 miles

Learn More »

A Dose Escalation Study of RO7082859 as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

This is a Phase I, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), RO7082859, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following the pre-treatment with a one-time, fixed dose of obinutuzumab. This ...

Phase

0.0 miles

Learn More »

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.

Phase

0.0 miles

Learn More »

Strategic Management to Optimize Response To Cardiac Resynchronization Therapy

The primary objective is to evaluate the benefit of the SmartDelay algorithm in patients with a prolonged RV-LV interval.

Phase N/A

0.0 miles

Learn More »

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

The primary purpose of this study is to describe the time to tolerization (i.e., ITI success) with rFVIIIFc in participants within a maximum of 48 weeks (12 months) of ITI treatment.

Phase

0.0 miles

Learn More »

Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)

To characterize dose response, and evaluate safety and efficacy of three different doses of EMA401 compared to placebo in patients with post-herpetic neuralgia (PHN)

Phase

0.0 miles

Learn More »

A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies

The purpose of this study is to determine if AMG 334 is effective in treating migraines in patients who have unsuccessfully failed other preventive migraine treatments.

Phase

0.0 miles

Learn More »

Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab

Study investigates benefit of treat to target maintenance treatment strategy versus routine care to test hypothesis that 'treat to target' ustekinumab (UST) maintenance treatment strategy coupled with early endoscopic assessment will result in higher endoscopic response rate after 48 weeks of treatment, compared to pragmatic maintenance treatment strategy. It consists ...

Phase

0.0 miles

Learn More »

Bortezomib Selinexor and Dexamethasone in Patients With Multiple Myeloma

This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 ...

Phase

0.0 miles

Learn More »